HUMAN SEL-10 POLYPEPTIDES AND POLYNUCLEOTIDES THAT ENCODE THEM

Abstract: The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides and cell lines which express them in which A beta processing is altered.

Description: Human Sel-10 Polypeptides and Polynucleotides that Encode Them FIELD OF THE INVENTION The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is a degenerative disorder of the central nervous system which causes progressive memory and cognitive decline during mid to late adult life. The disease is accompanied by a wide range of neuropathologic features including extracellular amyloid plaques and intra-neuronal neurofibrillary tangles. (Sherrington, R., et al; Nature 375: 754-60 (1995)). Although the pathogenic pathway leading to AD is not well understood, several genetic loci are known to be involved in the development of the disease. Genes associated with early onset Alzheimer's disease (AD) have been identified by the use of mapping studies in families with early-onset AD. These studies have shown that genetic loci on chromosomes 1 and 14 were likely to be involved in AD. Positional cloning of the chromosome 14 locus identified a novel mutant gene encoding an eight- transmembrane domain protein which subsequently was named presenilin-1 (PS-1). (Sherrington, R., et al; Nature 375: 754-60 (1995)). Blast search of the human EST database revealed a single EST exhibiting homology to PS-1, designated presenilin-2 (PS-2) which was shown to be the gene associated with AD on chromosome 1. (Levy-Lahad, E. et al, Science 269:913-911 (1995); Rogaev, E. I., et al, Nature 376: 775-8 (1995); Li, J. et al, Proc. Natl. Acad. Sci. U.S.A. 92: 12180-12184 (1995)). Mutations in PS-1 and PS-2 that are associated with Alzheimer's disease are primarily missense mutations. Both PS-1 and PS-2 undergo proteolytic processing, which can be altered by the point mutations found in familial Alzheimer's disease [Perez-Tur, J. et al, Neuroreport 7: 297-301 (1995); Mercken, M. et al, FEBS Lett. 389: 297-303 (1996)]. PS-1 gene expression is widely distributed across tissues, while the highest levels of PS-2 mRNA are found in pancreas and skeletal muscle. (Li, J. et al, Proc. Natl Acad. Sci. U.S.A. 92: 12180-12184 (1995); Jinhe Li, personal communication). The highest levels of PS-2 protein, however, are found in brain (Jinhe Li, personal communication). Both PS-1 and PS-2 proteins have been localized to the endoplasmic reticulum, the Golgi apparatus, and the nuclear envelope. (Jinhe Li, personal communication; Kovacs, D.M. et al, Nat. Med. 2:224- 229 (1996); Doan, A. et al, Neuron 17: 1023-1030 (1996)). Mutations in either the PS-1 gene or the PS-2 gene alter the processing of the amyloid protein precursor (APP) such that the ratio of A-betaι_ 42 is increased relative to A-beta^o (Scheuner, D. et al, Nat. Med. 2: 864- 870 (1996)). When coexpressed in transgenic mice with human APP, a similar increase in the ratio of as compared to is observed (Borchelt, D. R. et al, Neuron 17: 1005-1013 (1996); Citron, M. et al, Nat. Med. 3: 67-72 (1997); Duff, K. et al, Nature 383: 710-713 (1996)), together with an acceleration of the deposition of A-beta in amyloid plaques (Borchelt et al, Neuron 19: 939 (1997). Despite the above-described observations made with respect to the role of PS-1 and PS-2 in AD, their biological function remains unknown, placing them alongside a large number of human disease genes having an unknown biological function. Where the function of a gene or its product is unknown, genetic analysis in model organisms can be useful in placing such genes in known biochemical or genetic pathways. This is done by screening for extragenic mutations that either suppress or enhance the effect of mutations in the gene under analysis. For example, extragenic suppressors of loss-of-function mutations in a disease gene may turn on the affected genetic or biochemical pathway downstream of the mutant gene, while suppressers of gain-of-function mutations will probably turn the pathway off. One model organism that can be used in the elucidation of the function of the presenilin genes is C. elegans, which contains three genes having homology to PS-1 and PS-2, with sel-12 having the highest degree of homology to the genes encoding the human presenilins. Sel-12 was discovered in a screen for genetic suppressers of an activated notch receptor, /m-12(d) (Levitan, D. et al, Nature 377: 351-354 (1995)). Lin-\2 functions in development to pattern cell lineages. Hypermorphic mutations such as lin- 12(d), which increase lin-12 activity, cause a "multi-vulval" phenotype, while hypomorphic mutations which decrease activity cause eversion of the vulva, as well as homeotic changes in several other cell lineages (Greenwald, I., et al, Nature 346: 197-199 (1990); Sundaram, M. et al, Genetics 135: 755-763 (1993)). Se/-12 mutations suppress hypermorphic / n-12(d) mutations, but only if the lin- 12(d) mutations activate signaling by the intact lin- 12(d) receptor (Levitan, D. et al, Nature 377: 351-354 (1995)). Lin-12 mutations that truncate the cytoplasmic domain of the receptor also activate signaling (Greenwald, I., et al, Nature 346: 197-199 (1990)), but are not suppressed by mutations of sel-12 (Levitan, D. et al, Nature 377: 351-354 (1995)). This implies that sel-\2 mutations act upstream of the //n-12 signaling pathway, perhaps by decreasing the amount of functional lin-12 receptor present in the plasma membrane. In addition to suppressing certain lin-\2 hypermorphic mutations, mutations to sel-12 cause a loss-of-function for egg laying, and thus internal accumulation of eggs, although the mutants otherwise appear anatomically normal (Levitan, D. et al, Nature 377: 351-354 (1995)). Se/-12 mutants can be rescued by either human PS-1 or PS-2, indicating that sel-12, PS-1 and PS-2 are functional homologues (Levitan, D., et al, Proc. Natl. Acad. Sci. U.S.A 93: 14940-14944 (1996)). A second gene, sel-10, has been identified in a separate genetic screen for suppressors of //n-12 hypomoφhic mutations. Loss-of-function mutations in sel-10 restore signaling by //n-12 hypomoφhic mutants. As the lowering of sel-10 activity elevates lin-12 activity, it can be concluded that sel-10 acts as a negative regulator of lin-12 signaling. Sel-10 also acts as a negative regulator of sel-12, the C. elegans presenilin homologue (Levy-Lahad, E. et al, Science 269:913-911 (1995)). Loss of sel-10 activity suppresses the egg laying defect associated with hypomoφhic mutations in se/-12 (Iva Greenwald, personal communication). The effect of loss-of-function mutations to .se/-10 on //n-12 and sel-12 mutations indicates that sel-10 acts as a negative regulator of both lin-12/notch and presenilin activity. Thus, a human homologue of C. elegans sel-10 would be expected to interact genetically and/or physiologically with human presenilin genes in ways relevant to the pathogenesis of Alzheimer's Disease. In view of the foregoing, it will be clear that there is a continuing need for the identification of genes related to AD, and for the development of assays for the identification of agents capable of interfering with the biological pathways that lead to AD. INFORMATION DISCLOSURE Hubbard EJA, Wu G, Kitajewski J, and Greenwald I (1997) Sel-10, a negative regulator of lin-12 activity in Caenorhabditis elegans, encodes a member of the CDC4 family of proteins. Genes & Dev 1 1 : 3182-3193. Greenwald-I; Seydoux-G (1990) Analysis of gain-of-function mutations of the //n-72 gene of Caenorhabditis elegans. Nature. 346: 197-9 Kim T-W, Pettingell WH, Hallmark OG, Moir RD, Wasco W, Tanzi R (1997) Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J Biol Chem 272: 11006-11010. Levitan-D; Greenwald-I (1995) Facilitation of //n-72-mediated signalling by sel-12, a Caenorhabditis elegans S 182 Alzheimer's disease gene. Nature. 377: 351-4. Levitan-D; Doyle-TG; Brousseau-D; Lee-MK; Thinakaran-G; Slunt-HH; Sisodia-SS; Greenwald-I (1996) Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 93: 14940-4. Sundaram-M; Greenwald-I (1993) Suppressors of a lin-12 hypomoφh define genes that interact with both lin-12 and glp-1 in Caenorhabditis elegans. Genetics. 135: 765-83. Sundaram-M; Greenwald-I (1993) Genetic and phenotypic studies of hypomoφhic lin-12 mutants in Caenorhabditis elegans. Genetics. 135: 755-63. F55B12.3 GenPep Report (WMBL locus CEF55B12, accession z79757). WO 97/11956 SUMMARY OF THE INVENTION The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding human sel-10, which is expressed in hippocampal cells and in mammary cells. Unless otherwise noted, any reference herein to sel-10 will be understood to refer to human sel-10, and to encompass both hippocampal and mammary sel-10. Fragments of hippocampal sel-10 and mammary sel-10 are also provided. In a preferred embodiment, the invention provides an isolated nucleic acid molecule comprising a polynucleotide having a sequence at least 95% identical to a sequence selected from the group consisting of: (a) a nucleotide sequence encoding a human sel-10 polypeptide having the complete amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, or as encoded by the cDNA clone contained in ATCC Deposit No.98978; (b) a nucleotide sequence encoding a human sel-10 polypeptide having the complete amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, or as encoded by the cDNA clone contained in ATCC Deposit No. 98979; and (c) a nucleotide sequence complementary to the nucleotide sequence of (a) or (b). In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide encoding sel-10, or fragments thereof. The present invention also provides vectors comprising the isolated nucleic acid molecules of the invention, host cells into which such vectors have been introduced, and recombinant methods of obtaining a sel-10 polypeptide comprising culturing the above- described host cell and isolating the sel-10 polypeptide. In another aspect, the invention provides isolated sel-10 polypeptides, as well as fragments thereof. In a preferred embodiment, the sel-10 polypeptides have an amino acid sequence selected from the group consisting of SEQ ID NO:3, 4, 5, 6, 7, 8, 9, and 10. Isolated antibodies, both polyclonal and monoclonal, that bind specifically to sel-10 polypeptides are also provided. In another aspect a method for the identification of an agent capable of altering the ratio of Aβι. o + Aβ ( - 2 produced in a APP producing cell line is provided. In another aspect compounds capable of altering the ratio of Aβι. o Aβι- 40 + Aβι. 42 in an APP producing cell line are provided. In another aspect a method of altering the ratio of Aβι- { Aβ]- 40 + Aβι- 42 in the tissues or bodily fluids of a mammalian host which expresses one or more APP isotypes said method comprising administering to the host an amount of test agent effective to alter the ratio of Aβι- 40 / Aβι. 40 + Aβι- 42 is provided BRIEF DESCRIPTION OF THE FIGURES Figures 1A and IB: Figures 1A and IB are western blots showing protein expression in HEK293 cells transfected with PS l-C-FLAG, 6-myc-N-sel-10, and APP695NL-KK cDNAs. Figures 2A and 2B: Figures 2A and 2B are northern blots. Figure 2A is a multiple tissue northern blot probed with the common, mammary sel-10 mRNA showing ubiquitous expression of the 6.5- and 4.5-Kb transcripts. Figure 2B is a multiple tissue northern blot showing limited expression of the hippocampal sel-10 mRNA only in brain. Figures 3A, 3B and 3C. Figures 3A, 3B and 3C are western blots. Figure 3A demonstrates that SEL-10-myc forms a complex with PSI as shown by immunoprecipitation with anti-PS 1 loop antibody. HEK293 cells were transfected with constructs containing SEL-10-myc or PS I, cotransfected with both constructs, transfected with the corresponding vector only control (pcDNA3 or pCS, respectively), or mock transfected without DNA. Cultures were treated with lactacystin (12 μM) to inhibit proteasome function as indicated. The immunoprecipitates were loaded on the left side of the gel and cell lysates on the right. Controls for immunoprecipitation were a nonspecific IgG and just anti-PS 1 loop antibody with protein G beads with no cell lysate ("no protein"). The immunoblot was probed with anti-myc antibody to detect SEL-10-myc in the immunoprecipitates and cell lysates. SEL- 10-myc is expressed in lysates from cells transfected with SEL- 10-myc or cotransfected with SEL- 10-myc and PSI, but was detected only as a complex with PS I in cells cotransfected with the SEL-10-myc and PS I constructs. Figure 3B demonstrates that the SEL-10-myc PS 1 complex could be detected only when proteasome degradation was inhibited with lactacystin. Figure 3C demonstrates that immunoprecipitation of the SEL-10-myc/PS l complex with anti-myc antibody indicates that SEL-10-myc associates primarily with full length and high molecular weight forms of PS 1. Immunoprecipitates were probed with either anti-PS 1 loop or anti-myc antibodies. Longer exposures of the ECL developed Western blot reveal very low levels of PS 1-NTF in the immunoprecipitate with SEL-10-myc, but fail to detect PS1-CTF. Figures 4A and 4B. Figures 4A and 4B are western blots. Figure 4A demonstrates that SEL- 10-myc stimulates ubiquitination of PSI. An HEK293 cell line with stable expression of PS I was transfected with SEL-10-myc. Immunoprecipitation with an anti-PS 1 loop antibody was followed by detection with an anti-ubiquitin antibody. Figure 4B demonstrates that increased expression of SEL- 10-myc leads to a decrease in PS 1-NTF and PS 1-CTF with a corresponding increase in the amount of full length PS 1. Cell lysates were immunoprecipitated with anti-PS 1 loop antibody and then probed on the Western blot with the same antibody to detect PS 1 and its processing products. Figures 5A, 5B and 5C. Figures 5A, 5B and 5C are graphs. Figure 5A demonstrates that transient co-expression of SEL- 10-myc with APP increases production of Aβ 1 -40 and Aβ 1 - 42. The effect is additive with co-expressed PS I. Figure 5B demonstrates that stable expression of SEL-10-myc or PS I increases endogenous Aβ production. Figure 5C demonstrates that transient expression of APP in the stable cell lines increases exogenous Aβ production over the level seen in a cell line transformed with the pcDNA3.1 vector control. DETAILED DESCRIPTION OF THE INVENTION The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding human sel-10. The nucleotide sequence of human hippocampal sel-10 (hhsel-10), which sequence is given in SEQ ID NO: l, encodes five hhsel-10 polypeptides (hhsel-lθ-(l), hhsel-10-(2), hhsel-10-(3), hhsel-10-(4), and hhsel-10-(5), referred to collectively herein as hhsel-10). The nucleotide sequence of human mammary sel-10 (hmsel-10), which sequence is given in SEQ ED NO:2, encodes three hmsel-10 polypeptides (hmSel-lO-(l), hmSel-10-(2), and hmsel-10-(3), referred to collectively herein as hmsel-10). The nucleotide sequences of the hhsel-10 polynucleotides are given in SEQ ED NO. 1, where nucleotide residues 45-1928 of SEQ ID NO. 1 correspond to hhsel-lθ-(l), nucleotide residues 150-1928 of SEQ ID NO. 1 correspond to hhSel-10-(2), nucleotide residues 267-1928 of SEQ ID NO. 1 correspond to hhSel-10-(3), nucleotide residues 291-1928 of SEQ ID NO. 1 correspond to hhSel-10-(4), and nucleotide residues 306-1928 of SEQ ID NO. 1 correspond to hhSel-10-(5). The nucleotide sequences of the hmSel-10 polynucleotides are given in SEQ ID NO. 2, where nucleotide residues 180-1949 of SEQ ID NO. 2 correspond to hmSel-lO-(l), nucleotide residues 270-1949 of SEQ ID NO. 2 correspond to hmSel-10-(2), and nucleotide residues 327-1949 of SEQ ID NO. 2 correspond to hmSel-10-(3). The amino acid sequences of the polypeptides encoded by the hhSel-10 and hm-Sel-10 nucleic acid molecules are given as follows: SEQ ID NOS: 3, 4, 5, 6, and 7 correspond to the hhSel-lO-(l), hhSel-10-(2), hhSel-10-(3). hhSel-10-(4), and hhSel-10-(5) polypeptides, respectively, and SEQ ID NOS: 8, 9, and 10 correspond to the hmSel-lO-(l), hmSel-10-(2), and hmSel-10-(3) polypeptides, respectively. Unless otherwise noted, any reference herein to sel-10 will be understood to refer to human sel-10, and to encompass all of the hippocampal and mammary sel-10 nucleic acid molecules (in the case of reference to sel-10 nucleic acid, polynucleotide, DNA, RNA, or gene) or polypeptides (in the case of reference to sel-10 protein, polypeptide, amino acid sequnce). Fragments of hippocampal sel-10 and mammary sel-10 nucleic acid molecules and polypeptides are also provided. The nucleotide sequence of SEQ ID NO: l was obtained as described in Example 1, and is contained in cDNA clone PNV 102-1, which was deposited on November 9, 1998, at the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110, and given accession number 98978. The nucleotide sequence of SEQ ID NO:2 was obtained as described in Example 1, and is contained in cDNA clone PNV 108-2, which was deposited on November 9, 1998, at the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110, and given accession number 98979. The human sel-10 polypeptides of the invention share homology with C. elegans sel- 10, as well as with members of the β-transducin protein family, including yeast CDC4, and human LIS-1. This family is characterized by the presence of an F-box and multiple WD-40 repeats (Li, J., et al, Proc. Natl. Acad. Sci. U.S.A. 92: 12180-12184 (1995)). The repeats are 20-40 amino acids long and are bounded by gly-his (GH) and tφ-asp (WD) residues. The three dimensional structure of β-transducin indicates that the WD40 repeats form the arms of a seven-bladed propeller like structure (Sondek, J., et al, Nature 379:369-314 (1996)). Each blade is formed by four alternating pleats of beta-sheet with a pair of the conserved aspartic acid residues in the protein motif forming the limits of one internal beta strand. WD40 repeats are found in over 27 different proteins which represent diverse functional classes (Neer, E.J., et al, Nature 371:291-300 (1994)). These regulate cellular functions including cell division, cell fate determination, gene transcription, signal transduction, protein degradation, mRNA modification and vesicle fusion. This diversity in function has led to the hypothesis that β-transducin family members provide a common scaffolding upon which multiprotein complexes can be assembled. The nucleotide sequence given in SEQ ID NO:l corresponds to the nucleotide sequence encoding hhsel-10, while the nucleotide sequence given in SEQ ID NO:2 corresponds to the nucleotide sequence encoding hmsel-10. The isolation and sequencing of DNA encoding sel-10 is described below in Examples 1 and 2. As is described in Examples 1 and 2, automated sequencing methods were used to obtain the nucleotide sequence of sel-10. The sel-10 nucleotide sequences of the present invention were obtained for both DNA strands, and are believed to be 100% accurate. However, as is known in the art, nucleotide sequence obtained by such automated methods may contain some errors. Nucleotide sequences determined by automation are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule. The actual sequence may be more precisely determined using manual sequencing methods, which are well known in the art. An error in sequence which results in an insertion or deletion of one or more nucleotides may result in a frame shift in translation such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting at the point of the mutation. The sel-10 DNA of the present invention includes cDNA, chemically synthesized DNA, DNA isolated by PCR, genomic DNA, and combinations thereof. Genomic sel-10 DNA may be obtained by screening a genomic library with the sel-10 cDNA described herein, using methods that are well known in the art. RNA transcribed from se/-10 DNA is also encompassed by the present invention. Due to the degeneracy of the genetic code, two DNA sequences may differ and yet encode identical amino acid sequences. The present invention thus provides isolated nucleic acid molecules having a polynucleotide sequence encoding any of the sel-10 polypeptides of the invention, wherein said polynucleotide sequence encodes a sel-10 polypeptide having the complete amino acid sequence of SEQ ID NOs:3-10, or fragments thereof. Also provided herein are purified sel-10 polypeptides, both recombinant and non- recombinant. Variants and derivatives of native sel-10 proteins that retain any of the biological activities of sel-10 are also within the scope of the present invention. As is described above, the sel-10 polypeptides of the present invention share homology with yeast CDC4. As CDC4 is known to catalyze ubiquitination of specific cellular proteins (Feldman et al, Cell 91:221 (1997)), it may be inferred that sel-10 will also have this activity. Assay procedures for demonstrating such activity are well known, and involve reconstitution of the ubiquitinating system using purified human sel-10 protein together with the yeast proteins Cdc4p, Cdc53p and Skplp, or their human orthologs, and an El enzyme, the E2 enzyme Cdc34p or its human ortholog, ubiquitin, a target protein and an ATP regenerating system (Feldman et al, 1997). Skplp associates with Cdc4p through a protein domain called an F- box (Bai et al, Cell 86:263 (1996)). The F-box protein motif is found in yeast CDC4, C. elegans sel-10, mouse sel-10 and human sel-10. The sel-10 ubiquitination system may be reconstituted with the C. elegans counteφarts of the yeast components, e.g., cul-1 (also known as lin- 19) protein substituting for Cdc53p (Kipreos et al, Cell 85:829 (1996)) and the protein F46A9 substituting for Skplp, or with their mammalian counteφarts, e.g., Cul-2 protein substituting for Cdc53p (Kipreos et al, 1996) and mammalian Skplp substituting for yeast Skplp. A phosphorylation system provided by a protein kinase is also included in the assay system as per Feldman et al, 1997. Sel-10 variants may be obtained by mutation of native sel-10-encoding nucleotide sequences, for example. A sel-10 variant, as referred to herein, is a polypeptide substantially homologous to a native sel-10 but which has an amino acid sequence different from that of native sel-10 because of one or more deletions, insertions, or substitutions in the amino acid sequence. The variant amino acid or nucleotide sequence is preferably at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical, to a native sel-10 sequence. Thus, a variant nucleotide sequence which contains, for example, 5 point mutations for every one hundred nucleotides, as compared to a native sel-10 gene, will be 95% identical to the native protein. The percentage of sequence identity, also termed homology, between a native and a variant sel-10 sequence may also be determined, for example, by comparing the two sequences using any of the computer programs commonly employed for this puφose, such as the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wisconsin), which uses the algorithm of Smith and Waterman (Adv. Appl. Math. 2: 482-489 (1981)). Alterations of the native amino acid sequence may be accomplished by any of a number of known techniques. For example, mutations may be introduced at particular locations by procedures well known to the skilled artisan, such as oligonucleotide-directed mutagenesis, which is described by Walder et al. (Gene 42:133 (1986)); Bauer et al. (Gene 57:73 (1985)); Craik (BioTechniques, January 1985, pp. 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press (1981)); and U.S. Patent Nos. 4,518,584 and 4,737,462. Sel-10 variants within the scope of the invention may comprise conservatively substituted sequences, meaning that one or more amino acid residues of a sel-10 polypeptide are replaced by different residues that do not alter the secondary and/or tertiary structure of the sel-10 polypeptide. Such substitutions may include the replacement of an amino acid by a residue having similar physicochemical properties, such as substituting one aliphatic residue (He, Val, Leu or Ala) for another, or substitution between basic residues Lys and Arg, acidic residues Glu and Asp, amide residues Gin and Asn, hydroxyl residues Ser and Tyr, or aromatic residues Phe and Tyr. Further information regarding making phenotypically silent amino acid exchanges may be found in Bowie et al, Science 247:1306-1310 (1990). Other sel-10 variants which might retain substantially the biological activities of sel-10 are those where amino acid substitutions have been made in areas outside functional regions of the protein. In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a portion of the nucleic acid molecules described above, e.g., to at least about 15 nucleotides, preferably to at least about 20 nucleotides, more preferably to at least about 30 nucleotides, and still more preferably to at least about from 30 to at least about 100 nucleotides, of one of the previously described nucleic acid molecules. Such portions of nucleic acid molecules having the described lengths refer to, e.g., at least about 15 contiguous nucleotides of the reference nucleic acid molecule. By stringent hybridization conditions is intended overnight incubation at about 42/C for about 2.5 hours in 6 X SSC/0.1% SDS, followed by washing of the filters in 1.0 X SSC at 65/C, 0.1% SDS. Fragments of the sel-10-encoding nucleic acid molecules described herein, as well as polynucleotides capable of hybridizing to such nucleic acid molecules may be used as a probe or as primers in a polymerase chain reaction (PCR). Such probes may be used, e.g., to detect the presence of se/-10 nucleic acids in in vitro assays, as well as in Southern and northern blots. Cell types expressing sel-10 may also be identified by the use of such probes. Such procedures are well known, and the skilled artisan will be able to choose a probe of a length suitable to the particular application. For PCR, 5' and 3' primers corresponding to the termini of a desired sel-10 nucleic acid molecule are employed to isolate and amplify that sequence using conventional techniques. Other useful fragments of the sel-10 nucleic acid molecules are antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence capable of binding to a target sel-10 mRNA (using a sense strand), or sel-10 DNA (using an antisense strand) sequence. In another aspect, the invention includes sel-10 polypeptides with or without associated native pattern glycosylation. Sel-10 expressed in yeast or mammalian expression systems (discussed below) may be similar to or significantly different from a native sel-10 polypeptide in molecular weight and glycosylation pattern. Expression of sel-10 in bacterial expression systems will provide non-glycosylated sel-10. The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. Sel-10 polypeptides may be recovered and purified from recombinant cell cultures by well-known methods, including ammonium sulfate or ethanol precipitation, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. In a preferred embodiment, high performance liquid chromatography (HPLC) is employed for purification. The present invention also relates to vectors comprising the polynucleotide molecules of the invention, as well as host cell transformed with such vectors. Any of the polynucleotide molecules of the invention may be joined to a vector, which generally includes a selectable marker and an origin of replication, for propagation in a host. Because the invention also provides sel-10 polypeptides expressed from the polynucleotide molecules described above, vectors for the expression of sel-10 are preferred. The vectors include DNA encoding any of the sel-10 polypeptides described above or below, operably linked to suitable transcriptional or translational regulatory sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding sel-10. Thus, a promoter nucleotide sequence is operably linked to a sel-10 DNA sequence if the promoter nucleotide sequence directs the transcription of the sel-10 sequence. Selection of suitable vectors to be used for the cloning of polynucleotide molecules encoding sel-10, or for the expression of sel-10 polypeptides, will of course depend upon the host cell in which the vector will be transformed, and, where applicable, the host cell from which the sel-10 polypeptide is to be expressed. Suitable host cells for expression of sel-10 polypeptides include prokaryotes, yeast, and higher eukaryotic cells, each of which is discussed below. The sel-10 polypeptides to be expressed in such host cells may also be fusion proteins which include regions from heterologous proteins. Such regions may be included to allow, e.g., secretion, improved stability, or facilitated purification of the polypeptide. For example, a sequence encoding an appropriate signal peptide can be incoφorated into expression vectors. A DNA sequence for a signal peptide (secretory leader) may be fused in-frame to the sel-10 sequence so that sel-10 is translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cell promotes extracellular secretion of the sel-10 polypeptide. Preferably, the signal sequence will be cleaved from the sel-10 polypeptide upon secretion of sel-10 from the cell. Non-limiting examples of signal sequences that can be used in practicing the invention include the yeast I-factor and the honeybee melatin leader in sf9 insect cells. In a preferred embodiment, the sel-10 polypeptide will be a fusion protein which includes a heterologous region used to facilitate purification of the polypeptide. Many of the available peptides used for such a function allow selective binding of the fusion protein to a binding partner. For example, the sel-10 polypeptide may be modified to comprise a peptide to form a fusion protein which specifically binds to a binding partner, or peptide tag. Non-limiting examples of such peptide tags include the 6-His tag, thioredoxin tag, FLAG tag, hemaglutinin tag, GST tag, and OmpA signal sequence tag. As will be understood by one of skill in the art, the binding partner which recognizes and binds to the peptide may be any molecule or compound including metal ions (e.g., metal affinity columns), antibodies, or fragments thereof, and any protein or peptide which binds the peptide. These tags may be recognized by fluorescein or rhodamine labeled antibodies that react specifically with each type of tag Suitable host cells for expression of sel-10 polypeptides include prokaryotes, yeast, and higher eukaryotic cells. Suitable prokaryotic hosts to be used for the expression of sel-10 include bacteria of the genera Escherichia, Bacillus, and Salmonella, as well as members of the genera Pseudomonas, Streptomyces, and Staphylococcus. For expression in, e.g., E. coli, a sel-10 polypeptide may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in a prokaryotic host. The N-terminal Met may optionally then be cleaved from the expressed sel- 10 polypeptide. Expression vectors for use in prokaryotic hosts generally comprise one or more phenotypic selectable marker genes. Such genes generally encode, e.g., a protein that confers antibiotic resistance or that supplies an auxotrophic requirement. A wide variety of such vectors are readily available from commercial sources. Examples include pSPORT vectors, pGEM vectors (Promega), pPROEX vectors (LTI, Bethesda, MD), Bluescript vectors (Stratagene), and pQE vectors (Qiagen). Sel-10 may also be expressed in yeast host cells from genera including Saccharomyces, Pichia, and Kluveromyces. Preferred yeast hosts are S. cerevisiae and P. pastoris. Yeast vectors will often contain an origin of replication sequence from a 2T yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Vectors replicable in both yeast and E. coli (termed shuttle vectors) may also be used. In addition to the above-mentioned features of yeast vectors, a shuttle vector will also include sequences for replication and selection in E. coli. Direct secretion of sel-10 polypeptides expressed in yeast hosts may be accomplished by the inclusion of nucleotide sequence encoding the yeast I-factor leader sequence at the 5' end of the sel-10-encoding nucleotide sequence. -14- SUBST1TUTE SHEET (RULE 26) Insect host cell culture systems may also be used for the expression of Sel-10 polypeptides. In a preferred embodiment, the sel-10 polypeptides of the invention are expressed using a baculovirus expression system. Further information regarding the use of baculovirus systems for the expression of heterologous proteins in insect cells are reviewed by Luckow and Summers, Bio/Technology 6:47 (1988). In another preferred embodiment, the sel-10 polypeptide is expressed in mammalian host cells. Non-limiting examples of suitable mammalian cell lines include the COS-7 line of monkey kidney cells (Gluzman et al, Cell 23: 175 (1981)) and Chinese hamster ovary (CHO) cells. The choice of a suitable expression vector for expression of the sel-10 polypeptides of the invention will of course depend upon the specific mammalian host cell to be used, and is within the skill of the ordinary artisan. Examples of suitable expression vectors include pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). Expression vectors for use in mammalian host cells may include transcriptional and translational control sequences derived from viral genomes. Commonly used promoter sequences and enhancer sequences which may be used in the present invention include, but are not limited to, those derived from human cytomegalovirus (CMV), Adenovirus 2, Polyoma virus, and Simian virus 40 (SV40). Methods for the construction of mammalian expression vectors are disclosed, for example, in Okayama and Berg (Mol. Cell. Biol. 5:280 (1983)); Cosman et al. (Mol. Immunol. 25:935 (1986)); Cosman et al. (Nature 572:768 (1984)); EP-A-0367566; and WO 91/18982. The polypeptides of the present invention may also be used to raise polyclonal and monoclonal antibodies, which are useful in diagnostic assays for detecting sel-10 polypeptide expression. Such antibodies may be prepared by conventional techniques. See, for example, Antibodies: A Laboratory Manual, Hariow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988); Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet et al. (eds.), Plenum Press, New York (1980). The sel-10 nucleic acid molecules of the present invention are also valuable for chromosome identification, as they can hybridize with a specific location on a human chromosome. There is a current need for identifying particular sites on the chromosome, as few chromosome marking reagents based on actual sequence data (repeat polymoφhisms) are presently available for marking chromosomal location. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. The relationship between genes and diseases that have been mapped to the same chromosomal region can then be identified through linkage analysis, wherein the coinheritance of physically adjacent genes is determined. Whether a gene appearing to be related to a particular disease is in fact the cause of the disease can then be determined by comparing the nucleic acid sequence between affected and unaffected individuals. The sel-10 polypeptides of the invention, and the DNA encoding them, may also be used to further elucidate the biological mechanism of AD, and may ultimately lead to the identification of compounds that can be used to alter such mechanisms. The sel-10 polypeptides of the invention are 47.6% identical and 56.7% similar to C. elegans sel-10. As is described above, mutations to C. elegans sel-10 are known to suppress mutations to sel-12 that result in a loss-of-function for egg laying, and also to suppress certain hypomoφhic mutations to lin-12. Mutations to C. elegans sel-12 can also be rescued by either of the human AD-linked genes PS-1 (42.7% identical to sel-12) or PS-2 (43.4% identical to sel-12). However, human PS-1 with a familial AD-linked mutant has a reduced ability to rescue sel12 mutants (Levitan, D. et al, Proc. Natl. Acad. Sci. USA 93: 14940- 14944 (1996)). This demonstrated interchangeability of human and C. elegans genes in the notch signaling pathway makes it reasonable to predict that mutations of human sel-10 will suppress mutations to PS-1 or PS-2 that lead to AD, especially in light of the predicted structure of sel-10. As described above, PS-1 and PS-2 mutations that lead to AD are those which interfere with the proteolytic processing of PS-1 or PS-2. The sel-10 polypeptides of the invention are members of the β-transducin protein family, which includes yeast CDC4, a component of an enzyme which functions in the ubiquitin-dependent protein degradation pathway. Thus, human sel-10 may regulate presenilin degradation via the ubiquitin- proteasome pathway. Alternatively, or in addition, human sel-10 may alter presenilin function by targeting for degradation through ubiquitination a modulator of presenilin activity, e.g., a negative regulator. Therefore, mutations to se/-10 may reverse the faulty proteolytic processing of PS-1 or PS-2 which occurs as a result of mutation to PS-1 or PS-2 or otherwise increase presenilin function. For the same reason, inhibition of sel-10 activity may also act to reverse PS-1 or PS-2 mutations. Thus, it may be hypothesized that compounds which inhibit either the expression or the activity of the human sel-10 polypeptides of the invention may reverse the effects of mutations to PS-1 or PS-2, and thus be useful for the prevention or treatment of AD. -16- SUBST1TUTE SHEET (RULE 26) Thus, C. elegans may be used as a genetic system for the identification of agents capable of inhibiting the activity or expression of the human sel-10 polypeptides of the invention. A suitable C. elegans strain for use in such assays lacks a gene encoding active C. elegans sel-10, and exhibits a loss-of-function for egg-laying resulting from an inactivated sel- 12 gene. Construction of C. elegans strains having a loss-of-function for egg-laying due to mutation of se/-72 may be accomplished using routine methods, as both the sequence of sel- 12 (Genebank accession number U35660) and mutations to sel-12 resulting in a loss-of- function for egg laying are known (see Levitan et al. Nature 377: 351-354 (1995), which describes construction of C. elegans sel-12(arl71)). An example of how to make such a strain is also given in levitan et al. (Nature 377: 351-354 (1995)). Wild-type C. elegans sel-10 in the C. elegans sel-12(ar!71)) , is also mutagenized using routine methods, such as the technique used for sel-12 mutagenesis in Levitan et al, supra. In order to identify compounds inhibiting human sel-10 activity, a DNA vector containing a human sel-10 gene encoding any of the wild- type human sel-10 proteins of the invention is introduced into the above-described C. elegans strain. In a preferred embodiment, the heterologous human sel-10 gene is integrated into the C. elegans genome. The gene is then expressed, using techniques described in l ^ evitan et al. (Proc. Natl. Acad. Sci. USA 93: 14940-14944 (1996)). Test compounds are then administered to this strain in order to determine whether a given agent is capable of inhibiting sel-10 activity so as to suppress mutations to .se/-72 or //n-72 that result in egg-laying defects. Egg-laying in this strain is then determined, e.g. by the assay described in Levitan et al. (Proc. Natl. Acad. Sci. USA 93: 14940-14944 (1996)). To confirm that the compound's effect on egg-laying is due to inhibition of sel-10 activity, the action of the compound can be tested in a second biochemical or genetic pathway that is known to be affected by loss-of-function mutations in sel-10 (e.g., further elevation of lin-12 activity in lin- 12(d) hypomoφhic strains). Such assays may be performed as described in Sundarem and Greenwald (Genetics 135: 765-783 (1993)). Alternatively, compounds are tested for their ability to inhibit the E3 Ubiquitin Ligating Enzyme. Assays procedures for demonstrating such activity are well known, and involve reconstitution of the ubiquitinating system using purified human sel-10 protein together with the yeast proteins Cdc4p, Cdc53p and Skplp and an El enzyme, the E2 enzyme Cdc34p, ubiquitin, a target protein and an ATP regenerating system (Feldman et al, 1997). The sel-10 ubiquitination system may also be reconstituted with the C. elegans counteφarts of the yeast components, e.g., cul-1 (also known as lin- 19) protein substituting for Cdc53p (Kipreos et al, Cell &5:829 (1996)) and the protein F46A9 substituting for Skplp, or with their mammalian counteφarts, e.g., Cul-2 protein substituting for Cdc53p (Kipreos et al, ibid.) and mammalian Skplp substituting for yeast Skplp. A phosphorylation system provided by a protein kinase is also to be included in the assay system as per Feldman et al, 1997. Alternatively, cell lines which express human sel-10 due to transformation with a human sel-10 cDNA and which as a consequence have elevated APP processing and formation of Aβι- 40 or Aβι- 2 may also be used for such assays as in Example 3. Compounds may be tested for their ability to reduce the elevated Aβ processing seen in the sel-10 transformed cell line. Compounds that rescue the egg-laying defect or that inhibit E3 Ubiquitin Ligating Enzyme are then screened for their ability to cause a reduction in the production of A-beta^o or A-betaι- in a human cell line. Test compounds are used to expose IMR-32 or other human cell lines known to produce or A-betaι- 2 (Asami-Okada et al, Biochemistry 34: 10272-10278 (1995)), or in human cell lines engineered to express human APP at high levels. In these assays, is measured in cell extracts or after release into the medium by ELISA or other assays which are known in the art (Borchelt et al, Neuron 17: 1005-1013 (1996); Citron et al, Nat. Med. 3: 67-72 (1997)). It should appreciated that once one skilled in the art is in possession of methods of screening compounds for altering the ratio of Aβ^o Aβι_ o + Aβι_ 2 it is a matter of routine experimentation to put such compounds in the possession of the skilled artisan. It should also be appreciated that once such a skilled artisan is in possession of compounds have utility for altering the ratio of Aβι- 4 o + Aβι_ 42 development of a modality of treatment in animals and human for altering the Aβι_ 4 o + Aβι_ 42 in the tissues and bodily fluids of said animal or human is simply a matter of routine experimentation. Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting. EXAMPLES Example 1: Identification of a human homologue to C. elegans sel-10 Results Identification of sel-10 in ACEDB: Sel-10 maps between the cloned polymoφhisms arP3 and TCPARI just to the left of him-5 [ACEDB entry wm95p536]. Three phage lambda clones have been sequenced across the interval, F53C11, F09F3, and F55B12. Se/-70 is reported to have homology to yeast cdc4 [ACEDB entry wm97ab259]. Blast search revealed a single ORF with homology to yeast cdc4 (CC4_YST) within the interval defined by arP3 and TCPARI corresponding to the GenPep entry F55B 12.3. F55B12.3, like yeast cdc4, is a member of the β-transducin protein family. This family is characterized by the presence of multiple WD40 repeats [Neer, E.J. et al, Nature 371: 297-300 (1994)]. Identification of a human sel-10 homologue, Incyte 028971: The GenPep entry F55B12.3 was used to search the LifeSeq, LifeSeq FL and EMBL data bases using tblastn. The search revealed multiple homologies to β-transducin family members including LIS-1 (S36113 and P43035), a gene implicated in Miller-Dieker lissencephaly, a Xenopus laevis gene, TRCPXEN (U63921), and a human contig in LifeSeq FL, 028971. Since there also are multiple β-transducin family members within the C. elegans genome, these were collected using multiple blast searches and then clustered with the sel-10 candidate genes. Multiple alignments were performed with the DNAStar program Megalign using the Clustal method. This revealed that LIS-1 clustered with T03F6.F, a different β-transducin family member and thus excluded it as a candidate sel-10 homologue. TRCPXEN clustered with K10B2.1, a gene which also clusters with F55B12.3 and CC4YST, while Incyte 028971 clustered with sel-10. Thus, Incyte 028971 appears to encode the human homologue of C. elegans sel-10. Sequence homology between sel-10 and 028971 is strongest in the region of the protein containing 7 repeats of the WD40 motif. The Incyte 028971 contig contains 44 ESTs from multiple libraries including pancreas, lung, T-lymphocytes, fibroblasts, breast, hippocampus, cardiac muscle, colon, and others. Public EST: Blastx searches with the DNA sequence 028971 against the TREMBLP dataset identified a single homologous mouse EST (W85144) from the IMAGE Library, Soares mouse embryo NbME13.5-14.5. The blastx alignment of 028971 with W85144 and then with F55B12.3 revealed a change in reading frame in 028971 which probably is due to a sequencing error. Blastn searches of the EMBL EST database with the 028971 DNA sequence revealed in addition to W85144, three human EST that align with the coding sequence of 028971 and six EST that align with the 3' untranslated region of the 028971 sequence. Protein Motifs: Two protein motifs were identified in F55B12.3 which are shared with yeast cdc4, mouse w85144 and human 028971. These are an F-box in the N-terminal domain and seven β-transducin repeats in the C-terminal domain. Discussion The sel-10 gene encodes a member of the β-transducin protein family. These are characterized by the presence of multiple WD40 repeats [Neer, E.J. et al, Nature 371: 297- 300 (1994)]. The repeats are 20-40 amino acids long and are bounded by gly-his (GH) and tφ-asp (WD) residues. Solution of the three dimensional structure of β-transducin indicates that the WD40 repeats form the arms of a seven-bladed propeller like structure [Sondek, J. et al, Nature 379: 369-74 (1996)]. Each blade is formed by four alternating pleats of beta- sheet with a pair of the conserved aspartic acid residues in the protein motif forming the limits of one internal beta strand. WD40 repeats are found in over 27 different proteins which represent diverse functional classes [Neer, E.J. et al, Nature 371: 297-300 (1994)]. These regulate cellular functions including cell division, cell fate determination, gene transcription, signal transduction, protein degradation, mRNA modification and vesicle fusion. This diversity in function has led to the hypothesis that β-transducin family members provide a common scaffolding upon which multiprotein complexes can be assembled. The homology of sel-10, 28971 and W85144 to the yeast cdc4 gene suggests a functional role in the ubiquitin-proteasome pathway for intracellular degradation of protein. Mutations of the yeast cdc4 gene cause cell cycle arrest by blocking degradation of Sicl, an inhibitor of S-phase cyclin/cdk complexes [King, R.W. et al. Science 274: 1652-9 (1996)]. Phosphorylation of Sicl targets it for destruction through the ubiquitin-proteasome pathway. This pathway consists of three linked enzyme reactions that are catalyzed by multiprotein complexes [Ciechanover, A., Cell 79: 13-21 (1994); Ciechanover, A. and AL. Schwartz, FASEB J. 8: 182-91 (1994)]. Initially, the C-terminal glycine of ubiquitin is activated by ATP to form a high energy thiol ester intermediate in a reaction catalyzed by the ubiquitin- activating enzyme, El. Following activation, an E2 enzyme (ubiquitin conjugating enzyme) transfers ubiquitin from El to the protein target. In some cases, E2 acts alone. In others, it -20- SUBST1TUTE SHEET (RULE 26) acts in concert with an E3 ubiquitin-ligating enzyme which binds the protein substrate and recruits an E2 to catalyze ubiquitination. E2 ubiquitin-conjugating enzymes comprise a fairly conserved gene family, while E3 enzymes are divergent in sequence [Ciechanover, A., Cell 79: 13-21 (1994); Ciechanover, A. and A.L. Schwartz, FASEB J. 8: 182-91 (1994)]. In yeast, mutation of the E2 ubiquitin-conjugating enzyme, cdc34, causes cell cycle arrest through failure to degrade the Sicl inhibitor of the S-phase cyclin/cdk complex [King, R.W. et al, Science 274: 1652-9 (1996)]. Sicl normally is degraded as cells enter the Gl-S phase transition, but in the absence of cdc34, Sicl escapes degradation and its accumulation causes cell cycle arrest. Besides cdc34, cdc4 is one of three other proteins required for the Gl-S phase transition. The other two are cdc53 and Skpl. As discussed above, cdc4 contains two structural motifs, seven WD40 repeats (which suggests that the protein forms a beta-propeller) and a structural motif shared with cyclin F which is an interaction domain for Skpl [Bai, C. et al, Cell 86: 263-74 (1996)]. Insect cell lysates containing cdc53, cdc4 and skpl (and also ubiquitin, cdc34 and El) can transfer ubiquitin to Sicl suggesting that one or more of these components functions as an E3 ubiquitin-ligating enzyme [King, R.W. et al, Science 274: 1652-9 (1996)]. Increased expression of either cdc4 or Skpl partially rescues loss of the other. In C. elegans, mutation of sel-10 has no visible phenotype indicating that sel-10 does not play a role in regulation of the cell-cycle. A closely related, C. elegans β-transducin family member, K10B2.6 may play that role as it clusters with the gene TRCP_XEN from Xenopus laevis which rescues yeast cell cycle mutants arrested in late anaphase due to a failure to degrade cyclin B [Spevak,W. et al, Mol. Cell. Biol. 13: 4953-66 (1993)]. H sel-10 does encode a component of an E3-ubiquitin ligating enzyme, how might it suppress sel-12 and enhance //n-72 mutations? The simplest hypothesis is that sel-10 regulates degradation of both proteins via the ubiquitin-proteasome pathway. Both sel-12 and lin-12 are transmembrane proteins. Sel-72 crosses the membrane 8 times such that its N- and C- termini face the cytosol [Kim, T.W. et al, J. Biol. Chem. 272: 11006-10 (1997)], while lin- 12 is a type 1 transmembrane protein (Greenwald, I. and G. Seydoux, Nature 346: 197-9 (1990)). Both are ubiquitinated, and in the case of human PS2, steady state levels increase in cells treated with an inhibitor of the proteasome, N-acetyl-L-leucinal-L-norleucinal and lactacystin (Li, X. and I. Greenwald, Neuron. 17: 1015-21 (1996)). Alternatively, sel-10 may target for degradation of a negative regulator of presenilin function. -21- SUBST1TUTE SHEET (RULE 26) The genetic analysis and protein function suggested by homology to cdc4 implies that drug inhibitors of human sel-10 may increase steady state levels of human presenilins. This could potentiate activity of the presenilin pathway and provide a means for therapeutic intervention in Alzheimer's disease. Example 2: 5' RACE cloning of a human cDNA encoding Sel-10, an extragenic suppressor of presenilin mutations in C. elegans Materials and Methods Oligonucleotide primers for the amplification of the sel-10 coding sequence from C. elegans cDNA were prepared based on the sequence of F55B12.3, identified in Example 1 as the coding sequence for C. elegans sel-10. The primers prepared were: 5'-CGGGATCCACCATGGATGATGGATCGATGACACC-3' (SEQ ID NO: 11) and S'-GGAATTCCTTAAGGGTATACAGCATCAAAGTCG-S' (SEQ ID NO: 12). C. elegans mRNA was converted to cDNA using a BRL Superscript II Preamplification kit. The PCR product was digested with restriction enzymes Bam l and EcøRI (LTI, Gaithersberg, MD) and cloned into pcDNA3.1 (Invitrogen). Two isolates were sequenced (ABI, Perkin-Εlmer Coφ). The sequence of Incyte clone 028971 (encoding a portion of the human homologue of C. elegans sel-10), was used to design four antisense oligonucleotide primers: 5'- TCACTTCATGTCCACATCAAAGTCC-3' (SΕQ ID NO: 13), 5'-GGTAA- TTACAAGTTCTTGTTGAACTG (SΕQ ID NO: 14), 5 -CCCTGCAACGTGTGT- AGACAGG-3' (SΕQ ID NO: 15), and S'-CCAGTCTCTGCATTCCACACTTTG-S' (SΕQ ID NO: 16) to amplify the missing 5' end of human sel-10. The Incyte LifeSeq "Electronic Northern" analysis was used to identify tissues in which se/-10 was expressed. Two of these, hippocampus and mammary gland, were chosen for 5' RACE cloning using a CloneTech Marathon kit and prepared Marathon-ready cDNA from hippocampus and mammary gland. PCR products were cloned into the TA vector pCR3.1 (Invitrogen), and isolates were sequenced. An alternate 5' oligonucleotide primer was also designed based on Incyte clones which have 5' ends that differ from the hippocampal sel-10 sequence: S'-CTCAGACAGGTCAGGACATTTGG-S' (SEQ ID NO: 17 ). Blastn was used to search Incyte databases LifeSeq and LifeSeqFL. Gap alignments and translations were performed with GCG programs (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wisconsin). Results The coding sequence of the C. elegans sel-10: The predicted coding sequence of the C. elegans sel-10, F55B 12.3, had originally been determined at the Genome Sequencing Center, Washington University, St. Louis, by using the computer program GeneFinder to predict introns and exons in the genomic cosmid F55B12. The hypothetical cDNA sequence was confirmed by amplifying this region from C. elegans cDNA, cloning, and sequencing it . The coding sequence of the human sel-10 gene homologue: All of the 028971 antisense oligonucleotides amplified a 5' RACE product from human hippocampal and mammary cDNA. The longest PCR product from the hippocampal reactions was cloned and sequenced. This PCR reaction was designed to generate products which end at the predicted stop codon. Two isolates contained identical sequence which begins 880 bases before the beginning of the 028971 sequence. This sequence was confirmed by comparison with spanning Incyte cDNA clones. The Incyte clones that spanned the 5' end of the human sel- 10 homologue were not annotated as F55B12.3, as the homology in this region between the human and C. elegans genes is low, and as the overlap between these clones and the annotated clones happened to be too small for them to be clustered in the Incyte database or uncovered by our blasting the Incyte database with the 028971 sequence. The predicted protein sequences of human sel-10 have 47.6% identity and 56.7% similarity to C. elegans sel-10. The N-terminus of the human sel-10 sequence begins with 4 in-frame methionines. In addition to the WD40 repeats described above, the human sequence also contains a region homologous to the CDC4 F-box for binding Skpl, as expected for a sel-10 homologue. Different human sel-10 mRNAs expressed in mammary and hippocampal tissues: Several additional human sel-10 ESTs which differ from the hippocampal sequence were identified. These are an exact match, which indicates that the alternative transcript is probably real. Comparison of these sequences with the human hippocampal sel-10 sequence shows divergence prior to the 4th in-frame methionine and then exact sequence match thereafter. An oligonucleotide primer specific for the 5' end of this alternative transcript was found to amplify a product from mammary but not hippocampal cDNA. This indicates either that the human sel-10 transcript undergoes differential splicing in a tissue-specific fashion or that the gene contains multiple, tissue specific promoters. Discussion 5 'RACE and PCR amplification were used to clone a full-length cDNA encoding the human homologue of the C. elegans gene, sel-10. Sequence analysis confirms the earlier prediction that sel-10 is a member of the CDC4 family of proteins containing F-Box and WD40 Repeat domains. Two variants of the human sel-10 cDNA were cloned from hippocampus and mammary gland which differed in 5' sequence preceding the apparent site of translation initiation. This implies that the gene may have two or more start sites for transcription initiation which are tissue-specific or that the pattern of exon splicing is tissue- specific. EXAMPLE 3: Expression Of Epitope-Tagged Sel-10 In Human Cells , and PerturbationOf Amyloid β Peptide Processing By Human Sel-10 Materials And Methods Construction of Epitope-Tagged Sel-10: Subcloning, Cell Growth and Transfection: An EcoRl site was introduced in-frame into the human sel-10 cDNA using a polymerase chain reaction (PCR) primed with the oligonucleotides 237 (5'-GGAATTC- CATGAAAAGATTGGACCATGGTTCTG-3') (SEQ ID NO: 18) and 206 (5'-GGA- ATTCCTCACTTCATGT-CACATCAAAGTCCAG-3') (SEQ ID NO: 19). The resulting PCR product was cloned into the EcoRl site of the vector pCS2+MT. This fused a 5' 6- myc epitope tag in- frame to the fifth methionine of the hippocampal sel-10 cDNA, i.e., upstream of nucleotide 306 of the sequence given in SEQ ID NO: 1. The nucleotide sequence of this construct, designated 6myc-N-sel-10, is given in SEQ ID NO: 20, while the amino acid sequence of the polypeptide encoded thereby is given in SEQ ID NO: 21. The hippocampal and mammary sel-10 cDNA diverge upstream of this methionine. A PS 1 cDNA with a 3 '-FLAG tag (PSl-C-FLAG) was subcloned into the pcDNA3.1 vector. An APP cDNA containing the Swedish NL mutation and an attenuated ER retention sequence consisting of the addition of a di-lysyl motif to the C-terminus of APP695 (APP695NL-KK) was cloned into vector pIRES-EGFP (Mullan et al., Nat Genet 1992 Aug;l(5):345-7). HEK293 and IMR32 cells were grown to 80% confluence in DMEM with 10% FBS and transfected with the above cDNA. A total of 10 mg total DNA/6xl0 6 cells was used for transfection with a single plasmid. For cotransfections of multiple plasmids, an equal amount of each plasmid was used for a total of 10 mg DNA using LipofectAmine (BRL). In order to construct C-term V5 his tagged sel-10 and the C-term mychis tagged sel- 10, the coding sequence of human hippocampal sel-10 was amplified using oligonucleotides primers containing a Kpnl restriction site on the 5' primer: 5 -GGGTA- CCCCTCATTATTCCCTCGAGTTCTTC-3' (SEQ ED NO:22) and an EcoRl site on the 3' primer: 5'-GGAATTCCTTCATGTCCACATCAAAGTCC-3' (SEQ ID NO:23), using the original human sel-10 RACE per product as template. The product was digested with both Kpnl and EcoRl and cloned into either the vector pcDNA6/V5-His A or pcDNA3.1/Myc- His(+) A (Invitrogen). The nucleotide sequence of independent isolates was confirmed by dideoxy sequencing. The nucleotide sequence of the C-term V5 his tagged sel-10 is given in SEQ ID NO: 24, while the amino acid sequence of the polypeptide encoded thereby is given in SEQ ID NO: 25. The nucleotide sequence of independent isolates was confirmed by dideoxy sequencing. The nucleotide sequence of the C-term mychis tagged sel-10 is given in SEQ ID NO: 26, while the amino acid sequence of the polypeptide encoded thereby is given in SEQ ID NO: 27. Clonal Selection of transformed cells by FACS: Cell samples were analyzed on an EPICS Elite ESP flow cytometer (Coulter, Hialeah, FL) equipped with a 488 nm excitation line supplied by an air-cooled argon laser. EGFP emission was measured through a 525 nm band-pass filter and fluorescence intensity was displayed on a 4-decade log scale after gating on viable cells as determined by forward and right angle light scatter. Single green cells were separated into each well of one 96 well plate containing growth medium without G418. After a four day recovery period, G418 was added to the medium to a final concentration of 400 mg/ml. Wells with clones were expanded from the 96 well plate to a 24 well plate and then to a 6 well plate with the fastest growing colonies chosen for expansion at each passage. Immunofluorescence: Cells grown on slides were fixed 48 hrs after transfection with 4% formaldehyde and 0.1% Triton X-100 in PBS for 30 min on ice and blocked with 10% Goat serum in PBS (blocking solution) 1 hr RT (i.e., 25°C), followed by incubation with mouse anti-myc (10 mg/ml) or rabbit anti-FLAG (0.5 mg/ml) antibody 4°C O/N and then fluorescein-labeled goat anti-mouse or anti-rabbit antibody (5mg/ml) in blocking solution 1 hr at 25°C. Western blotting: Cell lysates were made 48 hrs after transfection by incubating 10 5 cells with 100 ml TENT (50 mM Tris-HCl pH 8.0, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, lx protease inhibitor cocktail) 10 min on ice followed by centrifugation at 14,000 g. The supernatant was loaded on 4-12% NuPage gels (50 mg protein/lane) and electrophoresis and transfer were conducted using an Xcell II Mini-Cell system (Novex). The blot was blocked with 5% milk in PBS 1 hr RT and incubated with anti-myc or anti- FLAG antibody (described in "Imrnunofluorescence" above) 4°C O/N, then sheep anti- mouse or anti-rabbit antibody-HRP (0.1 mg/ml) 1 hr RT, followed by Supersignal (Pierce) detection. ELISA: Cell culture supernatant or cell lysates (100 ml formic acid/10 6 cells) were assayed in the following double antibody sandwich ELISA, which is capable of detecting levels of Aβι_ 4 o and Aβι- 42 peptide in culture supernatant. Human Aβ 1-40 or 1-42 was measured using monoclonal antibody (mAb) 6E10 (Senetek, St. Louis, MO) and biotinylated rabbit antiserum 162 or 164 (NYS Institute for Basic Research, Staten Island, NY) in a double antibody sandwich ELISA. The capture antibody 6E10 is specific to an epitope present on the N-terminal amino acid residues 1-16 of hAβ. The conjugated detecting antibodies 162 and 164 are specific for hAβ 1-40 and 1- 42, respectively. The sandwich ELISA was performed according to the method of Pirttila et al. (Neurobiology of Aging 18: 121-7 (1997)). Briefly, a Nunc Maxisoφ 96 well immunoplate was coated with lOOμl/well of mAb 6E10 (5μg/ml) diluted in 0.1M carbonate-bicarbonate buffer, pH 9.6 and incubated at 4°C overnight. After washing the plate 3x with 0.01M DPBS (Modified Dulbecco's Phosphate Buffered Saline (0.008M sodium phosphate, 0.002M potassium phosphate, 0.14M sodium chloride, 0.01 M potassium chloride, pH 7.4) from Pierce, Rockford, II) containing 0.05% of Tween-20 (DPBST), the plate was blocked for 60 min with 200μl of 10% normal sheep serum (Sigma) in 0.01M DPBS to avoid non-specific binding. Human Aβ 1-40 or 1-42 standards lOOμl/well (Bachem, Torrance, CA) diluted, from a lmg/ml stock solution in DMSO, in non transfected conditioned cell medium was added after washing the plate, as well as lOOμl/well of sample i.e. filtered conditioned medium of transfected cells. The plate was incubated for 2 hours at room temperature and 4°C overnight. The next day, after washing the plate, lOOμl/well biotinylated rabbit antiserum 162 1:400 or 164 1:50 diluted in DPBST + 0.5% BSA was added and incubated at room temperature for lhr 15 min. Following washes, lOOμl/well neutravidin-horseradish peroxidase (Pierce, Rockford, II) diluted 1: 10,000 in DPBST was applied and incubated for 1 hr at room temperature. After the last washes lOOμl/well of o-phenylnediamine dihydrochloride (Sigma Chemicals, St. Louis, MO) in 50mM citric acid/lOOmM sodium phosphate buffer (Sigma Chemicals, St. Louis, MO), pH 5.0, was added as substrate and the color development was monitored at 450nm in a kinetic microplate reader for 20 min. using Soft max Pro software. Results Transfection ofHEK293 cells: Transfection efficiency was monitored through the use of vectors that express green fluorescent protein (GFP) or by immunofluorescent detection of epitope-tagged sel-10 or PSI. An N-terminal 6-myc epitope was used to tag human sel-10 (6myc-N-sel-10), while PS I was tagged with a C-terminal FLAG epitope (PSl-C-FLAG). APP695 was modified by inclusion of the Swedish NL mutation to increase Aβ processing and an attenuated endoplasmic reticulum (ER) retention signal consisting of a C-terminal di-lysine motif (APP695NL-KK). The di-lysine motif increases Aβ processing about two fold. The APP695NL-KK construct was inserted into the first cistron of a bicistronic vector containing GFP (pIRES-EGFP, Invitrogen) to allow us to monitor transfection efficiency. Transfection efficiency in HEK293 cells was about 50% for transfections with a single plasmid DNA. For cotransfections with two plasmids, about 30-40% of the cells expressed both proteins as detected by double immunofluorescence. Expression of recombinant protein in transfected HEK293 cells was confirmed by Western blot as illustrated for PSl-C-FLAG and 6myc-N-sel-10 (Fig 1A). In the case of cotransfections with three plasmids (PSl-C-FLAG + 6myc-N-sel-10 + APP), all three proteins were detected in the same cell lysate by Western blot (Figure IB) using appropriate antibodies. Effect of 6myc-N -sel-10 and PSl-C-FLAG on Aβ processing: Cotransfection of APP695NL-KK with 6myc-N-sel-10 or PS l-C-FLAG into HEK293 cells increased the release of Ab 1-40 and Abl-42 peptide into the culture supernatant by 2- to 3-fold over transfections with just APP695NL-KK (Table 1). Cotransfection of APP695NL-KK with both 6myc-N-sel-10 and PSl-C-FLAG increased Ab release still further (i.e., 4- to 6-fold increase). In contrast, the ratio of Abl-42/ (Abl-40 + Abl-42) released into the supernatant decreased about 50%. The subtle decrease in the ratio of Abl-42/ (Abl-40 + Abl-42) -27- SUBST1TUTE SHEET (RULE 26) reflects the larger increase in Ab 1-40 relative to Ab 1-42. Neither 6myc-N-sel-10 nor PS 1- C-FLAG affected endogenous Ab production in HEK293 cells. Similar observations were also obtained in IMR32 cells (Table 2). However, IMR32 cells transfected less well than HEK293 cells, so the stimulation of APP695NL-KK processing by cotransfection with 6myc-N-sel- 10 or PS 1 -C-FLAG was lower. Levels of Ab 1-40 expressed in HEK293 cells transfected with APP695NL-KK were sufficient to measure Ab peptide in both the culture supernatant and cell pellet. Considerably more Ab 1-40 is detected in the HEK293 cell pellet than in the supernatant in cells transfected with just APP695NL-KK. Cotransfection with 6myc-N-sel-10 or PS 1-C- FLAG proportionately decreased Ab 1-40 in the cell pellet and increased Ab in the culture supernatant. This implies that 6myc-N-sel-10 and PSl-C-FLAG alter processing or trafficking of APP such that proportionately more Ab is released from the cell. Effect of 6myc-N-sel-10 and PSl-C-FLAG expression on endogenous Aβ processing: The effect of 6myc-N-sel-10 on the processing of endogenous APP by human cells was assessed by creating stably transformed HEK293 cell lines expressing these proteins. Two cell lines expressing 6myc-N-sel-10 were derived (sel-10/2 & sel-10/6) as well as a control cell line transformed with pcDNA3.1 vector DNA. Both 6myc-N-sel-10 cell lines expressed the protein as shown by Western blot analysis. Endogenous production of Ab 1-40 was increased in both 6myc-N-sel-10 cell lines in contrast to vector DNA transformed cells Table 3). In addition, stable expression of 6myc-N-sel-10 significantly increased Ab production after transfection with APP695NL-KK plasmid DNA (Table 3). Similar results were obtained with 6 stable cell lines expressing PS 1 -C-FLAG. All 6 cell lines showed significant elevation of endogenous Aβ processing and all also showed enhanced processing of Ab after transfection with APP695NL-KK (Table 3). In addition, the increase of Aβ processing seen with 6myc-N-sel-10 was also seen with sel-10 tagged at the C-terminus with either mychis or v5his (See Table 4). Both C-terminal and N-terminal tags resulted in an increase in Aβ processing. Discussion These data suggest that , when over expressed, 6myc-N-sel-10 as well as PS1-C- FLAG alter Aβ processing in both transient and stable expression systems. A 6-myc epitope tag was used in these experiments to allow detection of sel-10 protein expression by Western blot analysis. If as its sequence homology to yeast CDC4 suggests, sel-10 is an E2-E3 ubiquitin ligase, it should be possible to identify the proteins it targets for ubiquitination. Since the presenilins are degraded via the ubiquitin-proteasome pathway, PS 1 & PS2 are logical targets of sel-10 catalyzed ubiquitination [Kim et al, J. Biol. Chem. 272: 11006-11010 (1997)]. How sel-10 affects Aβ processing is not understood at this point. In the future, it will be necessary to determine if sel-10 & PS 1 increase Aβ processing by altering production, processing, transport, or turn-over of APP, and whether the effect of PS 1 is mediated or regulated by sel-10. These experiments suggest that sel-10 is a potential drug target for decreasing Ab levels in the treatment of AD. They also show that C. elegans is an excellent model system in which to investigate presenilin biology in the context of AD. Thus, as is shown by cotransfection experiments, as well as in stable transformants, expression of 6myc-N-sellO or PSl-C-FLAG increases Aβ processing. An increase in Aβ processing was seen in both HEK293 cells and IMR32 cells after cotransfection of 6myc-N-sell0 or PS 1 -C-FLAG with APP695NL-KK. In stable transformants of HEK293 cells expressing 6myc-SellO or PSI - C-FLAG, an increase in endogenous Aβ processing was observed, as well as an increase in Aβ processing after transfection with APP695NL-KK. This suggests that inhibitors of either sel-10 and/or PSI, may decrease Aβ processing, and could have therappeutic potential for Alzheimer's disease. Example 4: SEL-10 Interacts with Presenilin 1, Facilitates Its Ubiquitination, and Alters Aβ Production Mutations in the presenilin genes (PS 1 or PS2) in man cause autosomal dominant early onset Alzheimer's disease. These have been linked to alterations in the processing of the amyloid protein precursor (APP) 1 2 . The presenilins are membrane proteins with 6-8 transmembrane domains 3 ' 4 , which localize to the endoplasmic reticulum, Golgi complex, nuclear envelope, kinetochore and centrosome 5 ' 6 . Mutations in sel-12, a Caenorhabditis elegans presenilin cause a defect in egg laying 7 . Sel-12 is one of three nematode presenilin 7 0 homologous (sel-12, hop-1 and spe-4) ' . The sel-12 mutant phenotype can be rescued by human PS 1 or PS2 10 , indicating that PS 1, PS2 and sel-12 are functional homologues. Mutations in sel-12 cause a defect in egg laying by altering signaling through the Notch///n- 72 pathway. The sel-12 mutant phenotype can be suppressed by loss of function mutations in a second gene, sel-10 ' ', which probably results in rescue of the egg laying defect by increasing the activity of a functionally redundant presenilin, hop-1 8 ' 9 . SEL-10 is a homologue of yeast Cdc4, a member of the SCF (Skpl-Cdc53/CULl-F-box protein) E2-E3 ubiquitin ligase family 12 . In this study, we show that human SEL-10 interacts with PS I and enhances PS 1 ubiquitination, thus altering cellular levels of unprocessed PS 1 and its N- and C-terminal fragments. This leads to an alteration in the metabolism of APP and to an increase in the production of amyloid β-peptide, the principal component of amyloid plaque in Alzheimer's disease 13 . The SCF E2-E3 ubiquitin ligases contain a catalytic core consisting of Skpl, Rbxl, Cdc53/CUL-1 and an E2 ubiquitin transferase, Cdc34 14 . These are targeted to substrates for ubiquitination by adapter proteins (e.g., Cdc4, Grrl, Met30, β-TrCP) containing an F- box motif and WD40 repeats 15 . There is evidence that presenilins are ubiquitinated and undergo degradation through the ubiquitin-proteasome pathway I6 ' . Physical interaction between C. elegans SEL-10 and SEL-12 has been shown previously u . Thus, SEL-10 may be the F-box adaptor protein that recruits presenilins for ubiquitination and subsequent degradation. Both human and mouse orthologs of C. elegans sel-10 have been identified in EST databases, although the sequence information is incomplete . We used rapid amplification of cDNA ends (RACE) to clone amplification products containing the full coding sequences for human and mouse sel-10. There are two variants of human sel-10 cDNA from hippocampus (hippocampus form) and mammary gland (common form) which differ in 5' sequence upstream of a common translation initiation site. This may indicate that the human sel-10 transcript undergoes differential splicing in a tissue-specific fashion or that the gene contains multiple, tissue specific promoters. The hippocampal form contains four in-frame methionines upstream of the common initiation site and the mammary form contains three. Whether or not these encode proteins with different N-termini is not known. The common transcript is ubiquitously expressed in all tissues tested (Fig 2A), while the hippocampal form is present only in brain (Fig 2B). The human sel-10 gene was localized to chromosome 4q31.2-31.3 by in situ hybridization (data not shown). The predicted protein sequences of human and C. elegans SEL-10 have 47.6% amino acid identity and 56.7% similarity. Human SEL-10 contains an F-box domain as found in other SCF family members. It also contains seven WD40/β-transducin repeats 18 as seen in yeast Cdc4p and C. elegans SEL-10, suggesting that the protein forms a seven-bladed propeller structure 19 . We first assessed the physical interaction of human SEL-10 and PS I. SEL-10 tagged with an N-terminal 6-Myc epitope and PS 1 were transiently co-expressed in human embryonic kidney cells (HEK293) and their interaction was assessed by immunoprecipitation. Complexes between SEL-10 and PS 1 could only be detected in the presence of a proteasome inhibitor, lactacystin, which was added to the cultures at the time of transfection. When immunoprecipitated with anti-PS 1 loop antibody, only the immuno- preciptate from cotransfected cells contained SEL- 10-myc (Fig 3 A), indicating that SEL-10 can interact with PS I. Since co-immunoprecipitation was not observed in cells without lactacystin treatment (Fig 3B), this suggests that the complex can only be captured by blocking the entry of PSI into the proteasome degradation pathway. The interaction between SEL-10 and PS 1 was confirmed in the reverse experiment by using anti-myc antibody for immunoprecipitation of SEL-10 (Fig 3C). PSI is cleaved within the cytoplasmic loop between transmembrane domains six and seven by an unknown protease which generates N- and C-terminal fragments (PS 1-NTF and PS 1-CTF, respectively). The SEL- 10-myc immunoprecipitates contained primarily full length and high molecular weight forms of PS 1, but only very low or undetectable amounts of PS 1-NTF and no PS 1-CTF. This suggests that SEL-10 may bind primarily to unprocessed PS 1. Next, we examined the effect of SEL-10 co-transfection on PSI ubiquitination. PSI immunoprecipitated from cotransfected cells contains a higher level of ubiquitination compared to cells transfected with PS 1 alone as shown by probing with anti-ubiquitin antibody (Fig 4A). This result demonstrates that complex formation between SEL-10 and PS 1 facilitates ubiquitination as implied previously by the need for lactacystin to demonstrate SEL-10/PS1 complex accumulation. We then investigated how ubiquitination affects PS 1 protein level. HEK293 cells were cotransfected with either SEL-10 or PS 1 alone or in combination and immunoprecipitates were probed with anti-PS 1 loop antibody (Fig. 4B). In cells cotransfected with PSI and SEL-10 in comparison to cells transfected with PSI alone, PS1- NTF and PS 1-CTF were decreased as were the high molecular weight forms of PSI. However, the amount of unprocessed PS 1 appeared to be slightly increased. There are several possible inteφretations of this complex cellular effect. The first is that SEL-10 mediated ubiquitination of PS 1-CTF and PS 1-NTF leads to their degradation. However, the fragments of PS I are not immunoprecipitated with SEL-10 suggesting that SEL-10 does not directly facilitate ubiquitination of PS 1-NTF and PS 1-CTF. The slight increase in unprocessed PSI seen in cells cotransfected with SEL-10 may suggest instead that SEL-10 binding to PS 1 or SEL-10 mediated ubiquitination of PSI inhibits proteolytic processing of PS 1-NTF and PS 1-CTF leading to accumulation of the unprocessed precursor. In order to examine the impact of SEL-10 mediated ubiquitination of PS 1 on amyloid β-peptide (Aβ) production, SEL-10 was expressed by either transient or stable transfection in HEK293 cells with or without wild-type PS I. Aβ peptide production was measured by enzyme immunoassays that could distinguish the 1-40 and 1-42 forms of the peptide. In transient expression experiments (Fig. 5 A), coexpression of SEL-10 with APP increased production and release of Aβ 1-40 and Aβl-42 by more than 2-fold in comparison to APP expression alone. Transient coexpression of PS 1 with APP also increased Aβl-40 and Aβl-42 levels by more than 3-fold, similar to previous reports although this is not a consistent finding 2 . Coexpression of SEL-10 and PS 1 with APP had an additive effect with an increase in Aβ production of approximately 7-fold. No effect on the ratio of Aβ 1- 42/total Aβ was observed with all values falling in the range 8.5% to 13.5%. The stimulation of Aβ processing due to expression of SEL-10 was consistently observed across experiments, however, the degree of stimulation did vary. To confirm and extend the result, a series of HEK293 cell lines were derived with stable expression of SEL-10 or PSI (Fig. 5B). The two SEL-10 cell lines obtained showed 4- and 7-fold increases in endogenous Aβl-40 peptide production compared to HEK293 cells transfected with just the pcDNA3.1 vector. Similarly, six cell lines with stable expression of PS 1 showed a 2- to 6-fold increase in endogenous Aβl-40 peptide production. Transient transfection of the stable cell lines with APP cDNA was performed to confirm and extend this result (Fig. 5C). Production of Aβ was greater in the SEL-10 and PS 1 cell lines in comparison to a control HEK293 cell line that had been transformed with just the pcDNA3.1 vector. Since SEL-10 decreases the cellular level of PS 1-NTF and PS 1-CTF fragments while slightly increasing unprocessed PS I, the increase in unprocessed PSI may be associated with the increase in Aβ peptide processing observed. Transient expression of PS 1 has a similar effect. It increases the cellular level of unprocessed PS 1 while having relatively little effect on the levels of PS 1- NTF and PS 1-CTF fragments. Our data indicate that SEL-10 interacts with PS 1 , stimulates PS 1 ubiquitination, and recruits it into the proteasome pathway for protein degradation. SEL-10 is likely to function as an adaptor protein that assembles the core catalytic complex of an SCF E2-E3 ubiquitin ligase 14 . Recognition of most SCF substrates by F-box/WD40 repeat adaptor proteins is phosphorylation dependent 15 , suggesting that this may be an additional level of cellular regulation of presenilin levels. To demonstrate complex formation between human SEL-10 and PS 1 in HEK293 cells required inhibition of proteasome function by lactacystin. In contrast, the C. elegans SEL-10/SEL-12 complex accumulates in human HEK293 cells in the absence of proteasome inhibitors suggesting that nematode SEL-10 is unable to assemble the human core catalytic complex ". Degradation of an eight-pass transmembrane protein such as presenilin presents a topological hurdle since the presenilin protein must be extracted from the membrane and delivered to the proteasome. Like presenilins, a number of other multipass integral membrane proteins with large cytoplasmic domains such as the cystic fibrosis transmembrane conductance regulator (CFTR) are degraded through the ubiquitin-proteasome pathway 2I ' 22 . This pathway also is important for quality control within the endoplasmic reticulum 23 and conceivably could impact on intracellular production of Aβ peptide. Transfection of PS 1 into human cells generally is observed to increase cellular levels of unprocessed PS 1, but causes little change in levels of PS 1-CTF and PS 1-NTF suggesting that processing is under tight cellular control 17 , perhaps due to their involvement in apoptotic pathways . As a consequence of increased transient or stable expression of PSI, we see an increase in Aβ peptide production that probably is due to the accumulation of unprocessed PS 1. A similar effect on Aβ peptide production and accumulation of unprocessed PSI is caused by increased expression of SEL-10. SEL-10 may directly regulate PS 1 processing by binding to the cleavage site in the large cytoplasmic loop of PS I, or SEL-10 mediated ubiquitination may block PSI processing. Similarly, a number of PS 1 mutations associated with familial Alzheimer's disease have been shown to decrease processing of PS 1 into N- and C-terminal fragments, although that is not a consistent finding . However, mutant forms of PS 1 are associated with a shift in the ratio of Aβ 1-42 and Aβl-40, whereas expression of wild-type PS I or SEL-10 has no effect on the ratio of Aβl-42/total Aβ 1 2 . The genetic data indicates that SEL-10 is a negative regulator of presenilin activity in C. elegans. Loss of SEL-10 function presumably rescues the egg laying defect in sel-12 mutant worms through facilitation of HOP- 1 presenilin activity, perhaps by allowing the increased accumulation of processed N- and C-terminal fragments of HOP- 1. Sel-10 was identified in a screen for mutations that increase presenilin activity ". In principle, genetic screens in model organisms such as C. elegans or Drosophila can be used to find mutations that decrease presenilin activity, the desired therapeutic goal in Alzheimer's disease 26 . Such screens have the potential to identify novel therapeutic targets for this devastating disease. Methods Cloning. Incyte clone (028971) was identified as the human homologue of C. elegans sel- 10 and its sequence was used to design four antisense oligonucleotide primers 5'-TCACT- TCATGTCCACATCAAAGTCC-3' (SEQ ID NO: _), 5'-GGTAATTACAAAGTTCTTG- TTGAACTG-3' (SEQ ID NO: _), 5'-CCCTGCAACGTGTGTAGACAGG-3' (SEQ ID NO: _), and 5'-CCAGTCTCTGCATTCCACACTTTG-3' (SEQ ID NO: _), to amplify the remainder of the human sel-10 sequence. "Electronic Northern" analysis revealed expression of sel-10 in hippocampus and mammary gland so these tissues were chosen for 5'RACE cloning using Marathon kit (CloneTech). Marathon-ready cDNA from hippocampus and mammary gland were prepared as directed in the kit. PCR products were cloned into the TA vector pCR3.1 (Invitrogen), and isolates were sequenced. An alternate 5' oligonucleotide primer was also designed based on Incyte clones that have 5' ends that differ from the hippocampal sel-10 sequence (5'-CTCAGACAGGTCAGGACATTTGG-3' (SEQ ID NO: ). Blastn was used to search the Incyte databases LifeSeq and LifeSeqFL. Gap alignments and translations were performed with GCG programs. Plasmids and transfections. The human sel-10 cDNA was inserted into the EcoRl site of the vector pCS2+MT (gift of Jan Kitajewski, Columbia University College of Physicians and Surgeons). This fused a 5' 6-myc epitope tag in- frame to the fifth methionine of the hippocampal sel-10 cDNA. The hippocampal and mammary sel-10 cDNA diverge upstream of this methionine. A PS 1 cDNA with a 3'-FLAG tag (PS 1 -C-FLAG) was inserted into the pcDNA3.1 vector. An APP cDNA containing the Swedish KM →NL mutation and an attenuated ER retention sequence consisting of a C-terminal di-lysine motif (APP695Sw-KK) was inserted into the pIRES-EGFP vector (Clontech). HEK293 cells were grown to 80% confluence in DMEM with 10% FBS and transfected with the above cDNAs. A total of 10 μg DNA/6 x 10 6 cells was used for transfection with a single plasmid. For cotransfections of multiple plasmids, an equal amount of each plasmid was used for a total of 10 μg DNA using LipofectAmine (BRL). Single cells were sorted into each well of one 96 well plate containing growth medium without G418 by FACS using an EPICS Elite ESP flow cytometer (Coulter, Hialeah, FL) equipped with a 488 nm excitation line supplied by an air-cooled argon laser. After a four day recovery period, G418 was added to the medium to a final concentration of 400 μg/ml for the selection of stably transfected cell lines. Stable expression of a cDNA was confirmed by detection of the specific protein or sequence tag by Western blot. Immunoprecipitation, Western blot, and ELISA. Aβ and PS 1 antibodies have been characterized . Cell lysates with equal amount of protein were precipitated with antibody and protein G-Sepharose at 4 °C for 2 hr and beads were washed three times with TENT buffer ' '. Immunoprecipitates were analyzed by Western blot using 4-12% NuPage Bis-Tris gel and PVDF membrane (Novex), peroxidase-conjugated secondary antibody (Vector) and SuperSignal West Pico Luminol Enhancer ( Pierce). The ELISA for Aβ 1-40 and Aβ 1-42 97 was performed as described . References: 1. Borchelt, D.R. et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta 1-42/ 1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013 (1996). 2. Citron, M. et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3, 67-72 (1997). 3. Doan, A. et al. Protein topology of presenilin 1. Neuron. 17, 1023-1030 (1996). 4. Li, X. & Greenwald, I. Membrane topology of the C. elegans SEL-12 presenilin. Neuron 17, 1015-1021 (1996). 5. De Strooper, B. et al. Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. J. Biol. Chem. 272, 3590-3598 (1997). 6. Li, J. et al., Alzheimer presenilins in the nuclear membrane, inteφhase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell 90, 917-927 (1997). 7. Levitan, D. & Greenwald, I. Facilitation of lin, 12, mediated signalling by sel, 12, a Caenorhabditis elegans S 182 Alzheimer's disease gene. Nature 377, 351- 4 (1995). 8. Li, X. & Greenwald, I. HOP, 1, a Caenorhabditis elegans presenilin, appears to be functionally redundant with SEL, 12 presenilin and to facilitate LIN, 12 and GLP, 1 signaling. Proc. Natl. Acad. Sci. U. S. A. 94,12204- 9 (1997). 9. Westlund, B. et al. Reverse genetic analysis of Caenorhabditis elegans presenilins reveals redundant but unequal roles for sel-12 and hop-1 in Notch-pathway signaling. Proc. Natl. Acad. Sci. U. S. A. 96, 2497-2502 (1999). 10. Levitan, D. et al. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 93, 14940-1494 (1996). 11. Wu, G. et al. Evidence for functional and physical association between Caenorhabditis elegans SEL, 10, a Cdc4p, related protein, and SEL, 12 presenilin. Proc. Natl. Acad. Sci. U. S. A. 95, 15787-1 (1998). 12. Hubbard, E. J. et al. Sel, 10, a negative regulator of lin, 12 activity in Caenorhabditis elegans, encodes a member of the CDC4 family of proteins. Genes. Dev. 1 1, 3182- 93 (1997). 13. Selkoe, D.J. Physiological production of the b-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 16, 403-409 (1993). 14. Tyers, M. & Willems, A.R. One ring to rule a superfamily of E3 ubiquitin ligases. Science 284, 601-604 (1999). 15. Patton, E.E. et al., Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis. Trends Genet. 14, 236-243 (1998). 16. Steiner, H. et al. Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J. Biol. Chem. 273, 32322-32331 (1998). 17. Kim, T. W. et al. Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J. Biol. Chem. 272, 11006-1 1010 (1997). 18. Neer E. J. et al. The ancient regulatory-protein family of WD-repeat proteins. Nature 371, 297-300, (1994). 19. Sondek, J. et al. Crystal structure of a G-protein beta gamma dimmer at 2.1 A resolution. Nature 379, 369-374 (1996). 20. Ancolio, K. et al. Alpha-secretase-derived product of beta-amyloid precursor protein is decreased by presenilin 1 mutations linked to familial Alzheimer's disease. J. Neurochem. 69, 2494-2499 (1997). 21. Ward, C. L. et al. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83, 121-127 (1995). 22. Johnston, J.A. et al. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143: 1883-1898 (1998). 23. Kopito, R. R. ER quality control: the cytoplasmic connection. Cell. 88, 427-430 (1997). 24. Zhang, Z. et al. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature. 395: 698-702 (1998). 25. Shirotani, K. et al. Effects of presenilin N-terminal fragments on production of amyloid b peptide and accumulation of endogenous presenilins. Neurosci. Let. 262, 37-40 (1999). 26. De Strooper, B. et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390 (1998). 27. Mehta, P.D. et al. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 241, 13-16 (1998). It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the invention. The entire disclosure of all publications cited herein are hereby incoφorated by reference. -39- SUBST1TUTE SHEET (RULE 26) - 40- SUBST1TUTE SHEET (RULE 26) 6142.P2CP Table 3. Endogenous and exogenous Abl-40 and Abl-42 levels in supematants from stable transformants of HEK293 cells. Stable Line GFP Transfection APP695NL-KK Transfection Abl-40 Abl-42 Abl-40 Abl-42 ng/ml ng/ml ng/ml ng/ml 6myc-N-sellO/2 2974- 29 1094-17 4877 + 547 750 + 32 6myc-N-sell0/6 1684-18 85-t-ll 8310 + 308 1391 + 19 PS1-C-FLAG/2 974-6 684-8 3348 + 68 493 + 21 ω c PS1-C-FLAG/8 1184-11 854-17 3516 + 364 515 + 36 CO PS1-C-FLAG/9 834-20 674-16 2369 + 73 350+ 12 PSI -C-FLAG/ 11 1524-17 684-13 4771+325 599 + 25 PSI -C-FLAG/ 12 1414- 12 504-10 4095 + 210 449 + 21 m PSI -C-FLAG/ 13 270- 139 61 -28 6983 + 304 745+41 CΛ pcDNA3/l 43+13 75+15 1960 + 234 61+6 x m m 3> 7" C ' m t σ> Table 4. Sel-10 constructs with epitope tags at the N or C terminus increase Aβ 1-40 and Aβ 1-42. 10 construct Aβ 1-40 %increase P- value Aβ 1-42 %increase P-value pcDNA 42401102 614± 10 6myc-N-sel-10 7631 ±465 80% 3.7 xlO 6 1136±73 46% 79x 10' sel-10-C-mychis 5485 + 329 29% 1.8 xlO 4 795 ±50 29% 40x 10' sel-10-CN5hιs 6210±498 46% 1.2 x 10 4 906 ± 73 48% 21 x 10'

Claims: What is claimed is: 1. An isolated nucleic acid molecule comprising a polynucleotide having a sequence at least 95% identical to a sequence selected from the group consisting of: (a) a nucleotide sequence encoding a human sel-10 polypeptide having the complete amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, or as encoded by the cDNA clone contained in ATCC Deposit No.98978; (b) a nucleotide sequence encoding a human sel-10 polypeptide having the complete amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, or as encoded by the cDNA clone contained in ATCC Deposit No. 98979; and (c) a nucleotide sequence complementary to the nucleotide sequence of (a) or (b). 2. An isolated nucleic acid molecule comprising polynucleotide which hybridizes under stringent conditions to a polynucleotide having the nucleotide sequence in (a), (b), or (c) of claim 1. 3. The nucleic acid molecule of claim 1, wherein said polynucleotide of 1(a) encodes a human sel-10 polypeptide having the complete amino acid sequence of SEQ ID NO:3. 4. The nucleic acid molecule of claim 3, wherein said polynucleotide molecule of 1(a) comprises the nucleotide sequence of residues 45-1928 of SEQ ID NO: l . 5. The nucleic acid molecule of claim 1, wherein said polynucleotide of 1(a) encodes a human sel-10 polypeptide having the complete amino acid sequence of SEQ ID NO:4. 6. The nucleic acid molecule of claim 5, wherein said polynucleotide molecule of 1(a) comprises the nucleotide sequence of residues 150-1928 of SEQ ID NO: l . 7. The nucleic acid molecule of claim 1, wherein said polynucleotide of 1(a) encodes a human sel- 10 polypeptide having the complete amino acid sequence of SEQ ID NO:5. 8. The nucleic acid molecule of claim 7, wherein said polynucleotide molecule of 1(a) comprises the nucleotide sequence of residues 267-1928 of SEQ ID NO: l. 9. The nucleic acid molecule of claim 1, wherein said polynucleotide of 1(a) encodes a human sel-10 polypeptide having the complete amino acid sequence of SEQ ID NO:6. 10 The nucleic acid molecule of claim 9, wherein said polynucleotide molecule of 1(a) comprises the nucleotide sequence of residues 291-1928 of SEQ ID NO: l. 1 1. The nucleic acid molecule of claim 1 , wherein said polynucleotide of 1(a) encodes a human sel-10 polypeptide having the complete amino acid sequence of SEQ ID NO:7. 12. The nucleic acid molecule of claim 1 1, wherein said polynucleotide molecule of 1(a) comprises the nucleotide sequence of residues 306-1928 of SEQ ID NO: l . 13. The nucleic acid molecule of claim 1, wherein said polynucleotide of 1(b) encodes a human sel-10 polypeptide having the complete amino acid sequence of SEQ ID NO:8. 14. The nucleic acid molecule of claim 13 wherein said polynucleotide molecule of 1(b) comprises the nucleotide sequence of residues 180-1949 of SEQ ID NO:2. 15. The nucleic acid molecule of claim 1, wherein said polynucleotide of 1(b) encodes a human sel-10 polypeptide having the complete amino acid sequence of SEQ ID NO:9. 16. The nucleic acid molecule of claim 15, wherein said polynucleotide molecule of 1(b) comprises the nucleotide sequence of residues 270-1949 of SEQ ID NO:2. 17. The nucleic acid molecule of claim 1, wherein said polynucleotide of 1(b) encodes a human sel-10 polypeptide having the complete amino acid sequence of SEQ ID NO: 10. 18. The nucleic acid molecule of claim 17, wherein said polynucleotide molecule of 1(b) comprises the nucleotide sequence of residues 327-1949 of SEQ ID NO:2. 19. A vector comprising the nucleic acid molecule of claim 1. 20. The vector of claim 19, wherein said nucleic acid molecule of claim 1 is operably linked to a promoter for the expression of a sel-10 polypeptide. 21. A host cell comprising the vector of claim 19. 22. The host cell of claim 21, wherein said host is a eukaryotic host. 23. A method of obtaining a sel-10 polypeptide comprising culturing the host cell of claim 22 and isolating said sel-10 polypeptide. 24. An isolated sel-10 polypeptide comprising ■ 44 - SUBST1TUTE SHEET (RULE 26) (a) an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, or as encoded by the cDNA clone contained in ATCC Deposit No. 98978; (b) an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, or as encoded by the cDNA clone contained in ATCC Deposit No. 98979. 25. The isolated sel-10 polypeptide of claim 24, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:3. 26. The isolated sel-10 polypeptide of claim 24, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:4. 27. The isolated sel-10 polypeptide of claim 24, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:5. 28. The isolated sel-10 polypeptide of claim 24, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:6. 29. The isolated sel-10 polypeptide of claim 24, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:7. 30. The isolated sel-10 polypeptide of claim 24, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:8. 31. The isolated sel-10 polypeptide of claim 24, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:9. 32. The isolated sel-10 polypeptide of claim 24, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 10. 33. An isolated antibody that binds specifically to the sel-10 polypeptide of claim 24. 34. A cell line having altered Aβ processing that expresses any of the sel- 10 isolated nucleic acid molecules of claim 1. 35. The cell line of claim 34, wherein said Aβ processing is increased. 36. The cell line of claim 34, wherein said Aβ processing is decreased. 37. The cell line of claim 34, wherein said cell line is 6myc-N-sell0/2. 38. The cell line of claim 34, wherein said cell line is 6myc-N-sellO/6. 39. A method for the identification of an agent capable of altering the ratio of Aβι- 0 / Aβι- 4 o + Aβι- 4 produced in any of the cell lines of claims 34, 37, and 38, comprising the steps of: (a) obtaining a test culture and a control culture of said cell line; (b) contacting said test culture with a test agent; (c) measuring the levels of Aβ o and Aβ^ 2 produced by said test culture of step (b) and said control culture; (d) calculating the ratio of Aβι_ 4 n + Aβ 1 - 42 for said test culture and said control culture from the levels of Aβι_ 0 and Aβι_ 42 measured in step (c); and (e) comparing the ratio of measured for said test culture and said control culture in step (d); whereby a determination that the ratio of Aβi- Aβι. o + Aβι_ 42 for said test culture is higher or lower than ratio of Aβι- 0 / Aβι- o + Aβι- 2 for said control culture indicates that said test agent has altered the ratio of Aβι- o/ Aβι- 4 o + Aβι^ 2 . 40. The method of claim 39, wherein said ratio of Aβι- 4 o/ Aβι- 4 o + Aβι. 42 is increased by said test agent. 41. The method of claim 39, wherein said ratio of Aβι. 4 o/ Aβι- 4 o + Aβι_ 42 is decreased by said test agent. 42. A test agent identified by the method of claim 39. 43. The test agent of claim 42 wherein said test agent is capable of decreasing the ratio of Aβι- o/ Aβι- 4 o+ Aβι_ 42 44. The test agent of claim 42 wherein said test agent is capable of increasing the ratio of Aβι. o/ Aβι- 4 o + Aβι^ 2. 45. A method of altering the ratio of Aβι- 4 o/ Aβι- 4 o + Aβι- 2 in the tissues or bodily fluids of a mammalian host which expresses one or more APP isotypes comprising the steps of: (a) identifying a test agent is capable of altering the ratio of Aβι. 4 o/ Aβ 1 ^ 0 + Aβι- 42 (b) administering to the host an amount of test agent effective to alter the ratio of Aβι- 40 / Aβ 1 . o + Aβι- 4 46. The method of claim 45 wherein the ratio of Aβι_ 40 / Aβι- 4 o+ Aβι. 42 is increased. 47. The method of claim 45 wherein the ratio of is decreased. 48. A method of altering the ratio of + Aβι- 42 in the tissues or bodily fluids of a mammalian host which expresses one or more APP isotypes said method comprising administering to the host an amount of test agent effective to alter the ratio of Aβι- 40 + 49. The method of claim 48 wherein the ratio of Aβ^o/ Aβι- o+ Aβι- 2 is increased. 50. The method of claim 48 wherein the ratio of Aβι- o/ Aβι. o+ Aβι- 42 is decreased. Human Sel-10 Polypeptides and Polynucleotides that Encode Them The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides and cell lines which express them in which Aβ processing is altered.

Inventors: GURNEY MARK E, LI JINHE, PAULEY ADELE M, GURNEY, MARK, E., LI, JINHE, PAULEY, ADELE, M.
Applicants: GURNEY MARK E, LI JINHE, PAULEY ADELE M, UPJOHN CO, GURNEY, MARK, E., LI, JINHE, PAULEY, ADELE, M., PHARMACIA & UPJOHN COMPANY
Application year: 2000
Main classification: C12N15
IPC codes: A61K45, A61P25, A61P43, C07K14, C07K16, C12N1, C12N5, C12N15, C12P21, C12Q1, G01N33